 |
|
|
|
|
Washington Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2022 replacing WashingtonLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
M3 Biotechnology, Inc.
| | | | | Phone: | (206) 616-4548 | | Year Established: | 2011 | | Employees: | 10 | | Main Contact: | Leen Kawas Ph.D., President & CEO | | | | Other Contacts: | John M. Fluke, Jr., Chairman
Josh Pan, PhD, MBA, Director of Business Development
Glenna Mileson, CFO
Joseph Harding, Ph.D., CSO
| | | | Company Description | | M3 Biotechnology is an innovative young therapeutics company that has a novel platform of pharmaceuticals that modifies growth-factor systems. M3’s initial development work has been supported by grants from both the Michael J. Fox Foundation and the Alzheimer’s Drug Discovery Foundation, financial support stemming from their understanding that M3’s technology represents a novel paradigm in the treatment of neurodegenerative diseases (NDDs). M3’s lead asset, MM-201, is being advanced as a first in class, orally available, Blood Brain Barrier permeate and disease-modifying treatment for Parkinson’s disease (PD) and Alzheimer’s disease (AD). | |
|
|
|
|
|
|
|
